Open AccessCorrelation Study on HLA-DR and CD117 (c-Kit) Expressions: Its Prognosis and Treatment Response in Acute Myeloid Leukemia Patients
Author(s) -
Yomna M El-Meligui,
Heba E Abd Elrhman,
A Salahuddin,
Manal Ali Hamouda,
Amira B. Kassem
Publication year - 2021
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s268986
Subject(s) - cd117 , medicine , myeloid leukemia , cd34 , gastroenterology , hla dr , myeloid , leukemia , myelodysplastic syndromes , human leukocyte antigen , cytogenetics , acute leukemia , oncology , bone marrow , immunology , antigen , biology , stem cell , gene , genetics , chromosome
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. HLA-DR and CD117 (c-Kit) are important diagnostic markers of AML. Our objective is to determine the prognostic significance of HLA-DR and CD117 expressions in newly diagnosed AML patients and determine the correlation between HLA-DR and CD117 expressions and other prognostic markers such as cytogenetic abnormalities, FLT3-ITD, response to treatment, and patient's survival.